MILLER INDUSTRIES INC /TN/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MILLER INDUSTRIES INC /TN/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $159.72M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $153.36M | Mar 7, 2018 |
| FY2017 | Jun 30, 2017 | $153.09M | Mar 7, 2018 |
| FY2017 | Mar 31, 2017 | $148.93M | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $148.59M | Mar 7, 2018 |
| FY2017 | Sep 30, 2016 | $147.60M | Mar 7, 2018 |
| FY2017 | Jun 30, 2016 | $156.11M | Mar 7, 2018 |
| FY2017 | Mar 31, 2016 | $148.82M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $136.44M | Mar 15, 2017 |
| FY2016 | Sep 30, 2015 | $126.21M | Mar 15, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $120.39M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $170.81M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $151.85M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $82.42M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $69.85M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $78.36M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $96.49M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $83.34M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $67.10M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $64.28M | Mar 6, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.01M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $63.49M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $58.29M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $20.35M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $16.26M | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | $12.02M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $6.55M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $5.83M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $5.43M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $11.69M | Mar 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $14.81M | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | $8.61M | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | $7.66M | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | $7.56M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $15.17M | Mar 3, 2021 |
| FY2020 | Sep 30, 2019 | $11.29M | Mar 3, 2021 |
| FY2020 | Jun 30, 2019 | $14.25M | Mar 3, 2021 |
| FY2020 | Mar 31, 2019 | $12.38M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $11.33M | Mar 4, 2020 |
| FY2019 | Sep 30, 2018 | $12.03M | Mar 4, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $6.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $6.00M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $4.00M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $3.60M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $4.72M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $3.70M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $3.13M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $1.94M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $1.80M | Mar 6, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.98M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $86.32M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $73.09M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $52.83M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $46.23M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $39.71M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $43.39M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $39.54M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $35.56M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $32.32M | Mar 6, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.72M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $16.87M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $10.96M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | ($19.16M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $15.27M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $60.71M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $35.13M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $21.90M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $13.95M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $20.93M | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.71M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $15.35M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $12.10M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $28.94M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $9.15M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $17.50M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $17.39M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $13.34M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $24.69M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $25.03M | Mar 6, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $589.67M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $667.02M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $647.21M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $501.43M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $437.64M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $398.41M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $391.97M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $368.18M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $317.24M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $297.44M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.10M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $265.99M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $299.29M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $207.97M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $153.03M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $115.96M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $134.04M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $140.62M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $114.14M | Mar 6, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $227.56M | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | $203.10M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $184.60M | Mar 6, 2019 |
| FY2018 | Dec 31, 2015 | $173.86M | Mar 6, 2019 |
| FY2017 | Dec 31, 2014 | $168.45M | Mar 7, 2018 |
| FY2016 | Dec 31, 2013 | $161.71M | Mar 15, 2017 |
| FY2013 | Dec 31, 2012 | $157.49M | Mar 5, 2014 |
| FY2012 | Dec 31, 2011 | $152.65M | Mar 6, 2013 |
| FY2012 | Dec 31, 2010 | $150.57M | Mar 6, 2013 |
| FY2012 | Dec 31, 2009 | $141.44M | Mar 6, 2013 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.07M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $20.00M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $20.02M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $11.62M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $11.62M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $11.62M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $11.62M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $11.62M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $11.62M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $11.62M | Mar 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $268.80M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $254.94M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $200.17M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $150.12M | Mar 6, 2024 |
| FY2023 | Dec 31, 2021 | $138.00M | Mar 6, 2024 |
| FY2023 | Dec 31, 2020 | $129.96M | Mar 6, 2024 |
| FY2022 | Dec 31, 2019 | $108.34M | Mar 8, 2023 |
| FY2019 | Jan 1, 2019 | $81.36M | Mar 4, 2020 |
| FY2019 | Dec 31, 2018 | $81.35M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $55.58M | Mar 6, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $27.04M | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | $21.90M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $31.12M | Mar 6, 2019 |
| FY2018 | Dec 31, 2015 | $38.45M | Mar 6, 2019 |
| FY2017 | Dec 31, 2014 | $39.60M | Mar 7, 2018 |
| FY2016 | Dec 31, 2013 | $42.86M | Mar 15, 2017 |
| FY2015 | Dec 31, 2012 | $48.59M | Mar 9, 2016 |
| FY2014 | Dec 31, 2011 | $50.15M | Mar 4, 2015 |
| FY2013 | Dec 31, 2010 | $46.33M | Mar 5, 2014 |
| FY2012 | Dec 31, 2009 | $36.16M | Mar 6, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2011 | $5.0K | Mar 6, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Mar 3, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 5 | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Mar 6, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Mar 3, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Mar 3, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.37M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 11.44M | Mar 4, 2026 |
| FY2022 | Dec 31, 2022 | 11.42M | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | 11.41M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 11.41M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 11.40M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 11.39M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | 11.38M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 11.35M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | 11.34M | Mar 15, 2017 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.15M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $8.72M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $8.25M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $8.22M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $8.22M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $8.21M | Mar 8, 2023 |
| FY2021 | Dec 31, 2019 | $8.21M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $8.20M | Mar 3, 2021 |
| FY2019 | Dec 31, 2017 | $8.19M | Mar 4, 2020 |
| FY2018 | Dec 31, 2016 | $7.72M | Mar 6, 2019 |